1. Clinical & Scientific Overview
Glipizide (TIP-MED-000051, Reference Code [4.7]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Second-Generation Short-Acting Sulfonylurea.
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.7], p. 48): Glynase / Glynase-XL (USV), Minidiab, Glide (Franco-Indian); In FDC with Metformin: Glynase-MF — Strengths & Dosage Forms: Immediate-Release (IR) Scored Tablets: 2.5 mg, 5 mg; Extended-Release (XL) Tablets: 5 mg, 10 mg
Immediate-Release (IR) Scored Tablets: 2.5 mg, 5 mg; Extended-Release (XL) Tablets: 5 mg, 10 mg
3. Mechanism of Action & Pharmacodynamics
Second-Generation Short-Acting Sulfonylurea acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Second-Generation Short-Acting Sulfonylurea for Type 2 diabetes mellitus (especially useful for targeting postprandial hyperglycaemia or in mild-to-moderate renal impairment)..
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 diabetes mellitus (especially useful for targeting postprandial hyperglycaemia or in mild-to-moderate renal impairment)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: IR: Initially 2.5 mg–5 mg once daily 30 minutes before breakfast (start at 2.5 mg in elderly or liver disease); doses >15 mg/day should be divided twice daily before breakfast and dinner (max 20–40 mg/day). XL: 5 mg–10 mg once daily with breakfast. Follow physician prescription.
Administration & Meal Timing: IR Tablets: Take 30 minutes BEFORE breakfast (and dinner if BD)—food delays glipizide IR absorption, so taking 30 minutes pre-meal achieves optimal insulin release matching the meal peak. (XL tablets are taken WITH breakfast). | Once daily in the morning, or twice daily before breakfast and dinner.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Metabolised in the liver to inactive metabolites; shorter half-life (2–5 hours) makes low-dose Glipizide IR safer than glibenclamide/glimepiride in moderate CKD, though start at 2.5 mg OD and monitor glucose closely. Hepatic: Initiate at 2.5 mg OD in mild hepatic impairment; avoid in severe cirrhosis.
Renal: Metabolised in the liver to inactive metabolites; shorter half-life (2–5 hours) makes low-dose Glipizide IR safer than glibenclamide/glimepiride in moderate CKD, though start at 2.5 mg OD and monitor glucose closely. Hepatic: Initiate at 2.5 mg OD in mild hepatic impairment; avoid in severe cirrhosis.
Renal: Metabolised in the liver to inactive metabolites; shorter half-life (2–5 hours) makes low-dose Glipizide IR safer than glibenclamide/glimepiride in moderate CKD, though start at 2.5 mg OD and monitor glucose closely. Hepatic: Initiate at 2.5 mg OD in mild hepatic impairment; avoid in severe cirrhosis.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in Type 1 DM, DKA, severe hepatic insufficiency, and sulfonamide allergy. Caution in G6PD deficiency. XL osmotic tablets (GITS) should not be used in severe GI stricture/narrowing.
Key Clinical Precautions: Renal: Metabolised in the liver to inactive metabolites; shorter half-life (2–5 hours) makes low-dose Glipizide IR safer than glibenclamide/glimepiride in moderate CKD, though start at 2.5 mg OD and monitor glucose closely. Hepatic: Initiate at 2.5 mg OD in mild hepatic impairment; avoid in severe cirrhosis.
8. Adverse Effects Profile
- Hypoglycaemia, dizziness, mild nausea, diarrhoea, weight gain.
- Severe neuroglycopenic hypoglycaemia, cholestatic jaundice, hyponatraemia/SIADH (rare), pancytopenia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Fluconazole, miconazole, cotrimoxazole, fluoroquinolones, fibrates, NSAIDs, and alcohol increase hypoglycaemic risk
- Colesevelam reduces glipizide absorption (take glipizide ≥4 hours prior)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Explain the 30-minute pre-meal rule for plain Glynase 5 mg: take the tablet 30 minutes before eating, but only once the meal is cooked and ready on the table so there is no risk of a kitchen delay causing low blood sugar. For Glynase-XL, inform patients that an insoluble outer tablet shell passes intact in the stool.
- Meal & Clock Timing Instruction: IR Tablets: Take 30 minutes BEFORE breakfast (and dinner if BD)—food delays glipizide IR absorption, so taking 30 minutes pre-meal achieves optimal insulin release matching the meal peak. (XL tablets are taken WITH breakfast). (Once daily in the morning, or twice daily before breakfast and dinner.)
- Missed Dose Protocol: If remembered after the meal has already started or finished, skip the missed dose to prevent delayed post-meal hypoglycaemia.
- Geriatric Dispensing Pearl: Start at 2.5 mg once daily in elderly patients; its short half-life reduces prolonged overnight hypoglycaemia compared to long-acting sulfonylureas.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release (IR) Scored Tablets: 2.5 mg, 5 mg; Extended-Release (XL) Tablets: 5 mg, 10 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.7] (p. 48)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.21] Semaglutide (Oral & Subcutaneous GLP-1 Receptor Agonist) — Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist (Schedule H)
- [4.22] Liraglutide & Dulaglutide (Injectable GLP-1 Receptor Agonists) — Subcutaneous GLP-1 Receptor Agonists (Schedule H | 2°C–8°C Cold C
- [4.23] Insulin Degludec (Ultra-Long Basal U-100 & Co-Formulation IDegAsp) — Ultra-Long-Acting Basal Insulin Analogue & Soluble Rapid+Basal Co
- [4.24] Glucagon & Oral / Intravenous Dextrose (Acute Severe Hypoglycaemia Protocol) — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
